Gastrointestinal Cancer Articles

Pembrolizumab Promising After Sorafenib in Advanced HCC
Treatment with the PD-1 inhibitor pembrolizumab elicited promising progression-free survival and overall survival results in patients with advanced hepatocellular carcinoma who received previous treatment with sorafenib.
Cetuximab Plus Pembrolizumab Well Tolerated in RAS Wild-Type mCRC
The combination of cetuximab and pembrolizumab was found to be well tolerated in patients with RAS wild-type metastatic colorectal cancer.
Lenvatinib Plus Pembrolizumab or Nivolumab Active in Intrahepatic Cholangiocarcinoma
Combining lenvatinib (Lenvima) with PD-1 inhibitors had promising efficacy in patients with advanced intrahepatic cholangiocarcinoma, according to preliminary data from a single-center study. 
Regorafenib Before Cetuximab Improves Survival in mCRC
Sequencing regorafenib before cetuximab showed superior overall survival compared with the reverse sequence in patients with metastatic colorectal cancer following failure of standard chemotherapy.
Nab-Paclitaxel/Gemcitabine Effective for Locally Advanced Pancreatic Cancer
Induction treatment with nab-paclitaxel plus gemcitabine demonstrated a time to treatment failure of 8.8 months for patients with newly diagnosed locally advanced pancreatic cancer.
Regorafenib Dose Escalation Superior in Metastatic CRC
Tanios Bekaii-Saab, MD, discusses the results and significance of the ReDOS study in metastatic colorectal cancer, as well as shared some insight on the Reverce trial.
Adding Ramucirumab to Frontline Chemo Does Not Improve Survival in Gastric Cancer
Adding ramucirumab to standard first-line chemotherapy significantly improved investigator-assessed progression-free survival compared with chemotherapy plus placebo in treatment-naive patients with HER2-negative gastric cancer.
Ramucirumab/Durvalumab Combination Shows Antitumor Activity in Gastric and GEJ Cancer
The combination of the VEGFR-2 inhibitor ramucirumab plus the anti-PD-L1 agent durvalumab demonstrated antitumor activity in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.
Trastuzumab Deruxtecan Active in HER2-Expressing Gastric Cancer
The novel investigational HER2-targeting antibody-drug conjugate trastuzumab deruxtecan showed promising antitumor activity in heavily pretreated patients with HER2-expressing gastric cancer.
Classifying NETs Versus NECs in Gastrointestinal Cancer
Jennifer Eads, MD, discusses the classification of NETs versus NECs in gastrointestinal cancer.
Publication Bottom Border
Border Publication